Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells

Acute myelogenous leukemia (AML) is frequently accompanied by a poor prognosis. The majority of patients with AML will experience recurrence due to multiple drug resistance. Our previous study reported that targeting the mTOR pathway may increase cell sensitivity to doxorubicin (Doxo) and provide an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Wang, Xiaozi, Ma, Chuanbao, Xu, Shasha, Xu, Mengyao, Yang, Jie, Wang, Ruicang, Xue, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930928/
https://www.ncbi.nlm.nih.gov/pubmed/34223631
http://dx.doi.org/10.3892/mmr.2021.11940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930928/
https://www.ncbi.nlm.nih.gov/pubmed/34223631
http://dx.doi.org/10.3892/mmr.2021.11940

Ejemplares similares